Drug Profile
FLK 2
Alternative Names: T-SCRLatest Information Update: 02 Apr 1997
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Amgen; ImClone Systems
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chemotherapy-induced damage
Most Recent Events
- 02 Apr 1997 New profile
- 02 Feb 1995 Discontinued-Preclinical for Chemotherapy induced damage/Chemoprotection in USA (Unknown route)